Evidence map›Paper›PMID 33118347›Full record

ArticleACS infectious diseases2020

Antimicrobial Prodrug Activation by the Staphylococcal Glyoxalase GloB.

Marwa O Mikati, Justin J Miller, Damon M Osbourn, Yasaman Barekatain, Naomi Ghebremichael, Ishaan T Shah, Carey-Ann D Burnham, Kenneth M Heidel, Victoria C Yan, Florian L Muller and 3 more

Open access · greenAbstract read
In one paragraph

Article in ACS infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Prodrug activation in malaria parasites mediated by an imported erythrocyte esterase, acylpeptide hydrolase (APEH).Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Marwa O MikatiDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Justin J MillerDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110, United States.ORCID 0000-0001-9400-8916
Damon M OsbournDepartment of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri 63104, United States.
Yasaman BarekatainDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States.
Naomi GhebremichaelDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Ishaan T ShahDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Carey-Ann D BurnhamDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Kenneth M HeidelDepartment of Chemistry, The George Washington University, Washington, DC 20052, United States.
Victoria C YanDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States.ORCID 0000-0003-0837-5184
Florian L MullerDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States.
Cynthia S DowdDepartment of Chemistry, The George Washington University, Washington, DC 20052, United States.
Rachel L EdwardsDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Audrey R Odom JohnDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110, United States.ORCID 0000-0001-8395-8537
Washington University in St. Louis · USThe University of Texas MD Anderson Cancer Center · USGeorge Washington University · USSaint Louis University · US

Funding

MEP pathway resistance in Plasmodium falciparumR01AI103280 · NIAID · WASHINGTON UNIVERSITY · PI Audrey Ragan Odom John · 2013 to 2026
$5.5M
Inhibition of MEP pathway Isoprenoid BiosynthesisR01AI123433 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI DOWD, CYNTHIA SCHIECK, MEYERS, MARVIN J · 2016 to 2020
$2.6M
TARGETING ISPC TO TREAT MALARIAR21AI123808 · NIAID · WASHINGTON UNIVERSITY · PI ODOM JOHN, AUDREY RAGAN · 2016 to 2017
$440k
SELECTIVE INHIBITION OF THE P. FALCIPARUM GLUCOSE TRANSPORTER PFHTR21AI130584 · NIAID · WASHINGTON UNIVERSITY · PI HRUZ, PAUL W · 2018 to 2019
$419k
GE AKTAEXPLORER CHROMOTOGRAPHY SYSTEMS10RR026891 · NCRR · WASHINGTON UNIVERSITY · PI ODOM JOHN, AUDREY RAGAN · 2010 to 2010
$122k
NCRR NIH HHS S10 RR026891NIAID NIH HHS R01 AI103280NIAID NIH HHS R01 AI123433NIAID NIH HHS R21 AI123808NIAID NIH HHS R21 AI130584
6 · The paper itself

Abstract

With the rising prevalence of multidrug resistance, there is an urgent need to develop novel antibiotics. Many putative antibiotics demonstrate promising

Indexed as

ProdrugsAnti-Bacterial AgentsEstersHumansStaphylococcusAnti-Bacterial AgentsEstersProdrugsantimicrobial resistancedrug developmentesteraseglyoxalaseprodrugStaphylococcus

Identifiers

PMID33118347
PMCPMC8543975
OpenAlexW3096621102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.